Skip to main content
Cancers logoLink to Cancers
. 2024 Mar 20;16(6):1211. doi: 10.3390/cancers16061211

Correction: Casili et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers 2023, 15, 2796

Giovanna Casili 1,†, Sarah Adriana Scuderi 1,†, Marika Lanza 1, Alessia Filippone 1, Deborah Mannino 1, Raffaella Giuffrida 2, Cristina Colarossi 2, Marzia Mare 2, Anna Paola Capra 1, Federica De Gaetano 1, Marco Portelli 3, Angela Militi 1, Salvatore Cuzzocrea 1, Irene Paterniti 1,*, Emanuela Esposito 1
PMCID: PMC10969352  PMID: 38539576

In the original publication [1], there was a mistake in Figure 4L as published. Figure 4I and Figure 4L were the same image, displayed with slightly different brightnesses. The corrected Figure 4 appears below.

Figure 4.

Figure 4

BAY-117082 treatment modulated the metastasis process in the lymph node, lung, and spleen. Histological analysis revealed that the treatment with BAY-117082 at doses of 2.5 and 5 mg/kg was able to reduce the degree of metastasis in the lymph node (C,D,M), lung (G,H,N), and spleen (K,L,O) in the C group compared with the OSCC group (B,F,J). (A,E,I) Control groups in the lymph node, lung, and spleen. Data are representative of at least three independent experiments. ND, not designed. *** p < 0.001 vs. sham; ### p < 0.001 and vs. ## p < 0.01 OSCC.

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Reference

  • 1.Casili G., Scuderi S.A., Lanza M., Filippone A., Mannino D., Giuffrida R., Colarossi C., Mare M., Capra A.P., De Gaetano F., et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC) Cancers. 2023;15:2796. doi: 10.3390/cancers15102796. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancers are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES